On June 17, 2021 Redx Pharma plc (AIM: REDX),the drug discovery and development company focused on cancer and fibrosis, reported that a milestone payment from AstraZeneca (NASDAQ: AZN) has been triggered as a result of progress in the development of RXC006,a preclinical porcupine inhibitor, targeting fibrotic diseases including idiopathic pulmonary fibrosis (IPF)(Press release, Redx Pharma, JUN 17, 2021, View Source [SID1234584098]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The milestone payment of$4 million has been triggered under the terms of the out licensing agreement announced on4 August 2020 and forms part of the previously announced $17 million in early payments between deal signature and the successful commencement of the first clinical trial.
Under this agreement, in addition to the $17 million in early payments, Redx may receive up to a further$360 million in development and commercial milestone payments throughout the course of the programme. The Company is also eligible to receive tiered royalties of mid-single digit percentages, based on any future net sales.
Porcupine inhibition is a novel anti-fibrotic approach that suppresses Wnt ligand secretion from pro-fibrotic cells. Wnt ligands are known to be strong drivers of fibrotic mechanisms and are highly expressed in diseases such as IPF. Wnt ligands regulate multiple aspects of disease biology so porcupine inhibition presents a potentially powerful anti-fibrotic approach. AstraZeneca is taking RXC006 forward into clinical development, targeting fibrotic diseases including IPF and anticipates entering clinical development in 2021.
Redx continues to execute on its strategy, progressing its lead oncology and fibrosis programmes. These include the oral porcupine inhibitor, RXC004, targeting Wnt-driven tumours, which is in an ongoing Phase 1 clinical trial in oncology patients, and the oral ROCK2 inhibitor, RXC007, which targets fibrosis, where first in human studies commenced in June 2021.
Lisa Anson, Chief Executive Officer of Redx Pharma commented: "We are extremely pleased that AstraZeneca are progressing RXC006 and the successful achievement of this milestone payment highlights, once again, Redx’s ability to generate molecules that have significant potential as novel medicines for unmet medical needs. We look forward to AstraZeneca progressing RXC006 into clinical trials and potentially delivering to patients who need new treatment options.